Lyra Therapeutics Inc


Prices are adjusted according to historical splits.

Lyra Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$172.91 million
Book Value:
Revenue TTM:
$1.24 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Lyra Therapeutics Inc had its IPO on 2020-05-01 under the ticker symbol LYRA.

The company operates in the Healthcare sector and Biotechnology industry. Lyra Therapeutics Inc has a staff strength of 73 employees.

Stock update

Shares of Lyra Therapeutics Inc opened at $5.04 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.32 - $5.25, and closed at $4.6.

This is a +7.48% increase from the previous day's closing price.

A total volume of 11,067,333 shares were traded at the close of the day’s session.

In the last one week, shares of Lyra Therapeutics Inc have increased by +31.81%.

Lyra Therapeutics Inc's Key Ratios

Lyra Therapeutics Inc has a market cap of $172.91 million, indicating a price to book ratio of 0.9628 and a price to sales ratio of 53.5353.

In the last 12-months Lyra Therapeutics Inc’s revenue was $1.24 million with a gross profit of $-34234000 and an EBITDA of $-60127000. The EBITDA ratio measures Lyra Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Lyra Therapeutics Inc’s operating margin was -4918.34% while its return on assets stood at -29.76% with a return of equity of -58.08%.

In Q2, Lyra Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 12.8%.

Lyra Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lyra Therapeutics Inc’s profitability.

Lyra Therapeutics Inc stock is trading at a EV to sales ratio of 1.5364 and a EV to EBITDA ratio of 0.3568. Its price to sales ratio in the trailing 12-months stood at 53.5353.

Lyra Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$125.68 million
Total Liabilities
$14.11 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Lyra Therapeutics Inc ended 2024 with $125.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $125.68 million while shareholder equity stood at $98.58 million.

Lyra Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $14.11 million in other current liabilities, 50000.00 in common stock, $-280548000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $54.36 million and cash and short-term investments were $116.15 million. The company’s total short-term debt was $1,688,000 while long-term debt stood at $0.

Lyra Therapeutics Inc’s total current assets stands at $118.25 million while long-term investments were $0 and short-term investments were $61.79 million. Its net receivables were $0 compared to accounts payable of $4.19 million and inventory worth $0.

In 2024, Lyra Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $71000.

Comparatively, Lyra Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Lyra Therapeutics Inc stock is currently trading at $4.6 per share. It touched a 52-week high of $6.48 and a 52-week low of $6.48. Analysts tracking the stock have a 12-month average target price of $12.33.

Its 50-day moving average was $3.41 and 200-day moving average was $2.89 The short ratio stood at 0.34 indicating a short percent outstanding of 0%.

Around 87.6% of the company’s stock are held by insiders while 6498.8% are held by institutions.

Frequently Asked Questions About Lyra Therapeutics Inc

The stock symbol (also called stock or share ticker) of Lyra Therapeutics Inc is LYRA

The IPO of Lyra Therapeutics Inc took place on 2020-05-01

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.


480 Arsenal Way, Watertown, MA, United States, 02472